Lisinopril dihydrate: Long-Acting ACE Inhibitor for Hypertension and Renal Research

Executive Summary: Lisinopril dihydrate (B3290) is a dihydrate formulation of lisinopril, a lysine analogue of MK 421 and a potent, long-acting ACE inhibitor with an IC₅₀ of 4.7 nM, enabling precise modulation of the renin-angiotensin system in research models (APExBIO). It selectively inhibits angiotensin converting enzyme (ACE; EC 3.4.15.1), reducing angiotensin II and aldosterone and elevating plasma renin, resulting in decreased blood pressure (Tieku & Hooper 1992). The compound is highly water-soluble, chemically stable when desiccated, and offers 98% purity by mass spectrometry and NMR (APExBIO). Lisinopril dihydrate is validated for experimental use in hypertension, heart failure, diabetic nephropathy, and acute myocardial infarction research. Its specificity, robust QC, and documented workflow compatibility make it a reference standard for modulation of the blood pressure regulation pathway.

Biological Rationale

Lisinopril dihydrate is an angiotensin converting enzyme inhibitor (ACE inhibitor) designed to interrupt the renin-angiotensin system—a critical regulator of blood pressure, electrolyte balance, and vascular resistance. ACE catalyzes the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. Inhibition decreases angiotensin II and aldosterone, leading to vasodilation and natriuresis (Tieku & Hooper 1992). This pathway is central to pathophysiology in hypertension, heart failure, diabetic nephropathy, and myocardial infarction. Lisinopril dihydrate, as a lysine derivative of the non-sulfhydryl ACE inhibitor MK 421, offers high selectivity with minimal off-target activity. Its stable dihydrate form enhances reproducibility in research workflows (APExBIO).

Mechanism of Action of Lisinopril dihydrate

Lisinopril dihydrate inhibits ACE (EC 3.4.15.1) with an IC₅₀ of 4.7 nM under standard assay conditions (37°C, pH 8.3, buffer: 100 mM HEPES, 300 mM NaCl) (Tieku & Hooper 1992). This blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstrictive and aldosterone-mediated sodium retention effects. The compound does not significantly inhibit other zinc metallopeptidases, including aminopeptidase N (AP-N; EC 3.4.11.2), aminopeptidase A (AP-A; EC 3.4.11.7), or aminopeptidase W (AP-W; EC 3.4.11.16) even at micromolar concentrations. This selectivity minimizes confounding effects in cardiovascular and renal disease models. The compound increases plasma renin activity and reduces both angiotensin II and aldosterone levels, leading to a marked reduction in blood pressure (Tieku & Hooper 1992).

Evidence & Benchmarks

• Lisinopril dihydrate exhibits an ACE inhibition IC₅₀ of 4.7 nM (purified porcine ACE; 37°C, pH 8.3) (Tieku & Hooper 1992).
• Does not inhibit AP-N, AP-A, or AP-W at up to 10 μM, supporting high target specificity (Tieku & Hooper 1992).
• Reduces plasma angiotensin II and aldosterone, increases plasma renin, and lowers blood pressure in animal models of hypertension (Tieku & Hooper 1992).
• Solubility in water is ≥2.46 mg/mL under gentle warming and ultrasonic treatment; insoluble in ethanol (APExBIO).
• Product purity is confirmed at 98% by mass spectrometry and NMR, batch verified (APExBIO).

For a comparative methodology and troubleshooting overview, see Lisinopril Dihydrate: Advanced ACE Inhibitor for Hypertension Research, which focuses on actionable protocols—this article extends those findings with updated selectivity and solubility data.

Applications, Limits & Misconceptions

Primary Research Applications:

• Hypertension research: Modulation of blood pressure via ACE inhibition.
• Heart failure studies: Reduction of cardiac afterload and fluid retention.
• Acute myocardial infarction models: Limiting adverse cardiac remodeling.
• Diabetic nephropathy: Mitigation of glomerular hypertension and proteinuria.

Lisinopril dihydrate is validated for use in both in vitro and in vivo experimental systems. It is not a clinical-grade formulation and is intended strictly for research purposes.

Common Pitfalls or Misconceptions

• Not effective on non-ACE zinc metallopeptidases: Lisinopril dihydrate does not inhibit AP-N, AP-A, or AP-W, so it cannot be used to probe these enzymes (Tieku & Hooper 1992).
• Not soluble in ethanol: Attempts to dissolve in organic solvents lead to precipitation; always dissolve in water with mild warming (APExBIO).
• Not intended for therapeutic use: This compound is for laboratory research only.
• Decomposition in solution over time: Stock solutions should not be stored long-term; prepare fresh aliquots (APExBIO).
• Not interchangeable with sulfhydryl ACE inhibitors: Does not share side-effect or inhibition profiles of sulfhydryl-containing agents.

For further clarification on selectivity boundaries, see Lisinopril dihydrate: Long-acting ACE Inhibitor for Hypertension, which this article updates with the latest specificity evidence and solubility recommendations.

Workflow Integration & Parameters

Lisinopril dihydrate (B3290) from APExBIO is supplied as a solid, molecular weight 441.52 g/mol, chemical formula C₂₁H₃₅N₃O₇. Recommended storage is desiccated, room temperature, avoiding prolonged solution storage. For dissolution, add water (≥2.46 mg/mL) with gentle warming (≤40°C) and ultrasonication if needed. Do not use ethanol. Shipping is on blue ice. Purity is lot-verified at ≥98% by mass spectrometry and NMR. QC data accompanies each batch. For robust results, incorporate into hypertension, heart failure, or renal disease models at doses calibrated for desired plasma ACE inhibition. For detailed scenario-driven troubleshooting, refer to Empowering Cell Assays with Lisinopril dihydrate, which this article extends by providing updated handling and specificity parameters.

Conclusion & Outlook

Lisinopril dihydrate remains a gold standard for selective, long-acting ACE inhibition in research. Its nanomolar potency, batch-verified purity, and robust solubility make it optimal for modeling hypertension, heart failure, and diabetic nephropathy. Provided by APExBIO, the B3290 kit ensures reproducibility and specificity. Future research will continue to leverage its unique profile to dissect the renin-angiotensin system and refine experimental cardiovascular and renal models.